Drug Trial Radar · NCT05245058
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jan 21, 2022
Primary completion
Dec 21, 2026
Study completion Dec 21, 2026
Sponsor
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 17, 2022
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors
Conditions
- HER2-positive Advanced Solid Tumors
Interventions
SPH5030 tabletsDrug
SPH5030 tablets orally once or twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: Up to 24 days
- Maximum tolerated dose(MTD)Time frame: Up to 24 days
- Number of patients with adverse eventsTime frame: Up to 2 years
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical University
Bengbu, China · Recruiting
The second people's hospital of neijiang
Neijiang, China · Recruiting
Tianjin Cancer Hospital Airport Hospital
Tianjin, China · Recruiting
Anhui provincial hospital
Hefei, Anhui, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Guangxi Cancer Hospital
Nanning, Guangxi, China · Recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Anyang Cancer Hospital
Anyang, Henan, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Linyi Cancer Hospital
Linyi, Shandong, China · Recruiting
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.